[1], [2], [3], [4] A 2021 retrospective study conducted at the Institute for Hormonal Balance in Orlando, Florida, that evaluated the use of BPC 157, alone or in combination with thymosin-beta-4 (TB4), indicates in its methodology that no human clinical trials evaluating the use of BPC 157 to help with knee pain have been published (see Table 1)
BPC-157 is often framed around repair and blood flow, while KPV is framed around immune signaling
Never spray directly onto the peptide powder
Specifically, observations suggest a potential reduction in neutrophil-associated responses alongside increased markers linked to vascular formation in GHK-Cu-exposed groups
Hollenstein K, de Graaf C, Bortolato A, Wang MW, Marshall FH, Stevens RC